Yu-Tzu Tai, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, comments on the potential of γ-secretase inhibitors to improve the efficacy of BCMA-targeted T-cell engagers in multiple myeloma without impairing T-cell effector function. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
